Adaptive Biotechnologies Corporation (ADPT)

NASDAQ

$15.70

+$0.26 (1.65%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$15.35$16.08

Open $16.03

52 Week Range

$5.80$20.76

Previous Close $15.44

Market Cap2.40B

Volume2.49M

Avg Volume2.25M

P/E (TTM)-19.69

EPS (TTM)$-0.80

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Adaptive Biotechnologies Corporation

DEC152025

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Source: GlobeNewsWire•22h ago

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research and development in multiple immunology application...

DEC92025

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Source: GlobeNewsWire•6 days ago

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di...

DEC62025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Source: GlobeNewsWire•9 days ago

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di...

NOV242025

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Source: GlobeNewsWire•21 days ago

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di...

NOV62025

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Source: GlobeNewsWire•39 days ago

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di...

NOV52025

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Source: GlobeNewsWire•40 days ago

SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical prod...

OCT152025

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Source: GlobeNewsWire•61 days ago

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat di...